Aspen Aerogels (ASPN) stock took a sharp dive in Monday's trading session, plummeting 7.25% following a significant downgrade from Barclays. The financial services giant revised its rating on Aspen Aerogels from Equal Weight to Underweight, signaling a more pessimistic outlook for the company's near-term prospects.

Adding to the bearish sentiment, Barclays also lowered its price target for Aspen Aerogels from $7 to $6. This double blow of a rating downgrade and reduced price target sparked a sell-off that began in pre-market trading, where the stock initially fell 5.83%, before extending losses as the regular session got underway.

The market's strong reaction to the Barclays report underscores the influence that major financial institutions can have on investor sentiment. With Aspen Aerogels now facing a more challenging outlook according to Barclays' analysis, investors appear to be reassessing their positions in the company. As trading continues, market participants will be closely watching to see if Aspen Aerogels can regain some ground or if this downgrade will continue to weigh on the stock's performance in the coming days.